The FDA approves vismodegib to treat BCC
The FDA has approved vismodegib for the treatment of patients with basal cell carcinoma (BCC), marking the first cancer therapeutic targeting the Hedgehog pathway to gain authorization.
Erivedge will be available in the United States within 2 weeks. Roche is pursuing marketing authorization in the European Union and patients there may be able to obtain the drug through a clinical trial.
... to read the full story